Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026

Vinge has advised Resurs in connection with its strategic partnership with Kustom

Vinge has advised Resurs in connection with its strategic partnership with Kustom (formerly Klarna Checkout), a fast-growing player in the digital commerce sector. The partnership enables Resurs to accelerate its strategic development by offering a check-out solution to its merchants, built on Kustom’s market-leading infrastructure.
March 25, 2026

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026